The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Olivera Finn receives Richard V. Smalley Memorial Award and Lectureship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Olivera Finn, University of Pittsburgh Distinguished Professor and founding chair of the Department of Immunology, was named the 2019 recipient of the Richard V. Smalley Memorial Award and Lectureship from the Society for Immunotherapy of Cancer, the society’s highest honor.

Finn is credited with identifying the first tumor-associated T cell target on human adenocarcinomas in 1989. Her research group also identified certain antibodies in cancers of the breast, pancreas and colon, which led to the development of a potential cancer vaccine currently being tested in clinical trials.

The Smalley Memorial Award, established by SITC in 2005, is presented annually to a clinician or scientist who has significantly contributed to the advancement of research in the field of cancer immunotherapy. The award is named in honor of the past SITC president and charter member of the society.

Finn is the former director of the Pitt Cancer Institute Cancer Immunology Program.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account